Evidence map›Paper›PMID 42529448›Full record

ArticlePhysics and imaging in radiation oncology2026

Deep learning-based generation of direct stopping power ratio maps for MR-only proton therapy of primary brain tumor patients.

Emilie Alvarez-Michael, Nils Peters, Julian Schwengfelder, Daniel Zachow, Felix Raschke, Steffen Löck, Christian Richter, Rudi Apolle, Franciska Lebbink, Esther G C Troost

Abstract read
In one paragraph

Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Emilie Alvarez-MichaelOncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Nils PetersOncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Julian SchwengfelderOncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Daniel ZachowOncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Felix RaschkeOncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Steffen LöckOncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Christian RichterOncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Rudi ApolleNational Center for Tumor Diseases Dresden (NCT/UCC), Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
Franciska LebbinkOncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Esther G C TroostOncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: A magnetic resonance-only proton therapy (MRoPT) workflow requires synthetic computed tomography (CT) to derive the stopping power ratio (SPR) for treatment planning. Here, we introduce three U-Net models to predict synthetic SPR (sSPR) maps from magnetic resonance imaging (MRI) scans of primary brain tumor patients. Materials and methods: SPR maps and heterogenous MRI data were collected from 140 patients. Three 2D-U-Net models were independently developed with axial, coronal, and sagittal MRI scan slices, the combination of which resulted in 2.5D sSPR.To evaluate the sSPR and associated dose maps, the mean absolute error (MAE), dose volume histogram-parameter differences, e.g. D2% and D98% of the clinical target volume (CTV), and the mean and maximum dose (Dmean and Dmax, respectively) for organs at risk (OAR; brainstem, optic chiasm, optic nerves, lacrimal glands and whole brain) were computed. Finally, gamma and range shifts analyses were performed. Results: The head cohort mean MAE was 0.062 ± 0.009 for the 2.5D sSPR. For the CTV, D2% and D98% differences ranged from -0.60% to 0.75%. Regarding the OAR, the Dmean and Dmax differences, corrected for relative biological effectiveness, were within ±2.70Gy (RBE). The mean pass rate for the local gamma criterion of 2%/2 mm with 10% dose threshold was 76.19 ± 4.67%. Averages of absolute range shifts ranged from 0.50 mm to 1.79 mm. Conclusions: Generated sSPR showed minor discrepancies from SPR. This study is a step closer to an MRoPT workflow for brain tumor patients, albeit the residual errors full impact needs to be more investigated in future work.

Indexed as

Deep learningMRIMR-only proton therapySynthetic stopping power ratio

Identifiers

PMID42529448
PMCPMC13416828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.